Literature DB >> 28939134

Reply to: "Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything" and "More extended indication of DAA therapy in patients with HCC, affordability, and further statistical considerations".

Lauren A Beste1, Pamela K Green2, Kristin Berry2, Matthew J Kogut3, Stephen K Allison3, George N Ioannou4.   

Abstract

Entities:  

Year:  2017        PMID： 28939134     DOI： 10.1016/j.jhep.2017.09.011

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  2 in total

1.  Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis.

Authors:  Yuki Tahata; Hayato Hikita; Satoshi Mochida; Nobuyuki Enomoto; Norifumi Kawada; Masayuki Kurosaki; Akio Ido; Daiki Miki; Hitoshi Yoshiji; Yasuhiro Takikawa; Ryotaro Sakamori; Yoichi Hiasa; Kazuhiko Nakao; Naoya Kato; Yoshiyuki Ueno; Hiroshi Yatsuhashi; Yoshito Itoh; Ryosuke Tateishi; Goki Suda; Taro Takami; Yasunari Nakamoto; Yasuhiro Asahina; Kentaro Matsuura; Taro Yamashita; Tatsuya Kanto; Norio Akuta; Shuji Terai; Masahito Shimizu; Satoshi Sobue; Tomokatsu Miyaki; Akihiro Moriuchi; Ryoko Yamada; Takahiro Kodama; Tomohide Tatsumi; Tomomi Yamada; Tetsuo Takehara
Journal:  J Gastroenterol       Date:  2022-01-20       Impact factor: 7.527

2.  NASH, Metabolic Syndrome, and Diabetes: How Sugar and Fat Increase the Risk of Developing Advanced Liver Disease.

Authors:  Paul Manka; Wing-Kin Syn
Journal:  Dig Dis Sci       Date:  2020-09-26       Impact factor: 3.199
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.